Healthcare | August 04, 2021
Mindpeers launches on-demand behavioural healthcare platform
It is designed to tackle mental health issues
It is designed to tackle mental health issues
This deal makes Meddo, one of the largest health-tech players in India
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Subscribe To Our Newsletter & Stay Updated
